Richtlijn Diabetische retinopathie - Nederlands Oogheelkundig ...
Richtlijn Diabetische retinopathie - Nederlands Oogheelkundig ... Richtlijn Diabetische retinopathie - Nederlands Oogheelkundig ...
R i s i c o f a c t o r e n e n p r e v e n t i e26. Henricsson M, Nilsson A, Janzon L, Groop L. The effect of glycaemic control and the introduction of insulintherapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 1997;14:123-31.27. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. Randomised placebo-controlled trial ofhuman recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependentdiabetes mellitus. Lancet 1997;350:1199-204.28. Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, et al. Metabolic control andprogression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and HumanDevelopment diabetes in early pregnancy study. Diabetes Care 1995;18:631-7.29. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascularcomplications in type 2 diabetes: UKPDS 38. Brit Med J 1998;317:703-13. Erratum in: Brit Med J 1999;318:29.30. Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am JOphthalmol 2001;132(5):760-76. Review.31. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care 2004;27:2540-53.32. Yoshida Y, Hagura R, Hara Y, Sugasawa G, Akanuma Y. Risk factors for the development of diabetic retinopathyin Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2001;51:195-203.33. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, et al for ARIC Group. The association of atherosclerosis,vascular risk factors, and retinopathy in adults with diabetes : the atherosclerosis risk in communities study.Ophthalmology 2002;109:1225-34.34. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipidlevels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS)Report 22. Arch Ophthalmol 1996;114:1079-84.35. Leiden HA van, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood pressure, lipids, and obesity areassociated with retinopathy: the Hoorn study. Diabetes Care 2002;25:1320-5.36. Leiden HA van, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Risk factors for incident retinopathy ina diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol 2003;121:245-51.37. Janghorbani M, Jones RB, Murray KJ, Allison SP. Incidence of and risk factors for diabetic retinopathy in diabeticclinic attenders. Ophthalmic Epidemiol 2001;8:309-25.38. Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol Metab Clin NorthAm 2002;31:779-93.41
- Page 1 and 2: RichtlijnDiabetische retinopathie
- Page 3 and 4: ColofonDiabetische retinopathieScre
- Page 5 and 6: D i a b e t i s c h e r e t i n o p
- Page 8: Screening, diagnostiek en behandeli
- Page 11 and 12: D i a b e t i s c h e r e t i n o p
- Page 13 and 14: D i a b e t i s c h e r e t i n o p
- Page 15 and 16: D i a b e t i s c h e r e t i n o p
- Page 17 and 18: D i a b e t i s c h e r e t i n o p
- Page 19 and 20: D i a b e t i s c h e r e t i n o p
- Page 22 and 23: Hoofdstuk 1Algemene inleiding1.1 Do
- Page 24 and 25: A l g e m e n e i n l e i d i n gwo
- Page 26 and 27: A l g e m e n e i n l e i d i n gzo
- Page 28 and 29: A l g e m e n e i n l e i d i n gDe
- Page 30 and 31: Hoofdstuk 2Achtergrond2.1 Pathofysi
- Page 32 and 33: A c h t e r g r o n dmellitus type
- Page 34 and 35: Hoofdstuk 3Risicofactoren en preven
- Page 36 and 37: R i s i c o f a c t o r e n e n p r
- Page 38 and 39: R i s i c o f a c t o r e n e n p r
- Page 40 and 41: R i s i c o f a c t o r e n e n p r
- Page 44 and 45: Hoofdstuk 4ScreeningInleidingIn dit
- Page 46 and 47: S c r e e n i n ggevonden dat direc
- Page 48 and 49: S c r e e n i n gFundusfotografieNi
- Page 50 and 51: S c r e e n i n gop basis van een o
- Page 52 and 53: S c r e e n i n gde drie maanden, a
- Page 54 and 55: S c r e e n i n gNiveau 4Niveau 4Ni
- Page 56 and 57: S c r e e n i n g21. Herbert HM, Jo
- Page 58 and 59: Hoofdstuk 5DiagnostiekInleidingIn d
- Page 60 and 61: D i a g n o s t i e kOverige overwe
- Page 62 and 63: D i a g n o s t i e kScreening en d
- Page 64 and 65: D i a g n o s t i e kIndextest: fun
- Page 66 and 67: Hoofdstuk 6BehandelingInleidingZoal
- Page 68 and 69: B e h a n d e l i n gLasercoagulati
- Page 70 and 71: B e h a n d e l i n gNiveau 2Panret
- Page 72 and 73: Hoofdstuk 7Cataractextractie bij pa
- Page 74 and 75: C a t a r a c t e x t r a c t i e b
- Page 76: C a t a r a c t e x t r a c t i e b
- Page 79 and 80: D i a b e t i s c h e r e t i n o p
- Page 81 and 82: D i a b e t i s c h e r e t i n o p
- Page 84 and 85: Hoofdstuk 9AppendicesAppendix 1. Ge
- Page 86 and 87: A p p e n d i c e sNICEIn een omsla
- Page 90: EBRO-richtlijn Diabetische retinopa
R i s i c o f a c t o r e n e n p r e v e n t i e26. Henricsson M, Nilsson A, Janzon L, Groop L. The effect of glycaemic control and the introduction of insulintherapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 1997;14:123-31.27. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. Randomised placebo-controlled trial ofhuman recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependentdiabetes mellitus. Lancet 1997;350:1199-204.28. Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, et al. Metabolic control andprogression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and HumanDevelopment diabetes in early pregnancy study. Diabetes Care 1995;18:631-7.29. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascularcomplications in type 2 diabetes: UKPDS 38. Brit Med J 1998;317:703-13. Erratum in: Brit Med J 1999;318:29.30. Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am JOphthalmol 2001;132(5):760-76. Review.31. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care 2004;27:2540-53.32. Yoshida Y, Hagura R, Hara Y, Sugasawa G, Akanuma Y. Risk factors for the development of diabetic retinopathyin Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2001;51:195-203.33. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, et al for ARIC Group. The association of atherosclerosis,vascular risk factors, and retinopathy in adults with diabetes : the atherosclerosis risk in communities study.Ophthalmology 2002;109:1225-34.34. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipidlevels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS)Report 22. Arch Ophthalmol 1996;114:1079-84.35. Leiden HA van, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood pressure, lipids, and obesity areassociated with retinopathy: the Hoorn study. Diabetes Care 2002;25:1320-5.36. Leiden HA van, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Risk factors for incident retinopathy ina diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol 2003;121:245-51.37. Janghorbani M, Jones RB, Murray KJ, Allison SP. Incidence of and risk factors for diabetic retinopathy in diabeticclinic attenders. Ophthalmic Epidemiol 2001;8:309-25.38. Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol Metab Clin NorthAm 2002;31:779-93.41
Change language